1,857 reports of this reaction
1.8% of all METHYLPHENIDATE HYDROCHLORIDE reports
#9 most reported adverse reaction
SOMNOLENCE is the #9 most commonly reported adverse reaction for METHYLPHENIDATE HYDROCHLORIDE, manufactured by Sandoz Inc. There are 1,857 FDA adverse event reports linking METHYLPHENIDATE HYDROCHLORIDE to SOMNOLENCE. This represents approximately 1.8% of all 101,957 adverse event reports for this drug.
Patients taking METHYLPHENIDATE HYDROCHLORIDE who experience somnolence should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SOMNOLENCE is a less commonly reported adverse event for METHYLPHENIDATE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to somnolence, the following adverse reactions have been reported for METHYLPHENIDATE HYDROCHLORIDE:
The following drugs have also been linked to somnolence in FDA adverse event reports:
SOMNOLENCE has been reported as an adverse event in 1,857 FDA reports for METHYLPHENIDATE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
SOMNOLENCE accounts for approximately 1.8% of all adverse event reports for METHYLPHENIDATE HYDROCHLORIDE, making it a notable side effect.
If you experience somnolence while taking METHYLPHENIDATE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.